Avidbiotics’ Martin talks to BioWorld News & Views about ‘bacterial warfare’ and infectious diseases
By: BioWorld News & Views | Source: BioWorld You Tube Channel
David Martin, CEO and Co-founder, Avidbiotics Corp. explained to BioWorld why heads are turning in the last year or two related to microbiome R&D. He also provided updates on the status of Avidbiotics’ two candidates for C. diff and E. coli.
http://youtu.be/8px8hgsO5AY?list=UUZg4UA-D_6q_-DuDyDrEg3w
Read or purchase full article from: BioWorld You Tube Channel
Press Releases
Pylum Biosciences Collaborates on Research Published in the Journal Nature
AvidBiotics’ Scientists Co-author Publication in Science Translational Medicine Describing A New Class of Targeted Antibacterial Agents for Clostridium difficile
Study Published in mBio Shows that Avidocin™ Proteins Prevent Clostridium Difficile Infection in Mice without Harming Protective Gut Bacteria
AvidBiotics Granted U.S. Patent for Bactericidal Proteins that Selectively Kill C. Difficile
AvidBiotics Awarded SBIR Grant for Avidocin™ Antibacterial Proteins Against Clostridium difficile
Articles